Drug Profile
Research programme: monoclonal antibodies - BioInvent International/Mitsubishi Tanabe Pharma
Alternative Names: Antibodies for inflammation - BioInvent/Japanese companyLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator BioInvent International
- Developer BioInvent International; Mitsubishi Tanabe Pharma Corporation
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Unspecified
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Unspecified in Japan (Parenteral)
- 31 Dec 2018 Preclinical development is ongoing in Japan
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Japan (Parenteral)